UBS Downgrades GlaxoSmithKline (GSK) to Neutral
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $40.86 --0%
Rating Summary:
8 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
8 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
UBS downgraded GlaxoSmithKline (NYSE: GSK) from Buy to Neutral.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $45.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
- Truist Securities Double Downgrades Monster Beverage (MNST) to Sell
- UBS Upgrades UDR, Inc. (UDR) to Buy
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
